Key facts
- This page summarizes Gerald Bagg's Form 4 filing for Cure Pharmaceutical Holding Corp. (AVRW).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 15 Sep 2022, 18:11.
Gerald Bagg - 25 Jul 2022 Form 4 Insider Report for Cure Pharmaceutical Holding Corp. (AVRW)
- Reporting relationship
- Director
- Issuer ticker
- AVRW
- Reported as of
- 25 Jul 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Sep 2022, 18:11:35 UTC
- Prior SEC filing
- 23 Aug 2022
- Next SEC filing
- 21 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joel M. Bennett, Attorney-in-Fact for Gerald Bagg
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gerald Bagg filed Form 4 for Cure Pharmaceutical Holding Corp. (AVRW) on 15 Sep 2022.
Change
- Previous filing in this sequence was filed on 23 Aug 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AVRW
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +220,795
- Change %
- Price
- $0.000000
- Shares after
- 220,795
- Date
- 25 Jul 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This late filing is due to an inadvertent administrative error and not any error of the Reporting Person.
Footnote F2
Represents the grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan pursuant to the Issuer's Non-Employee Director Compensation Policy. The RSUs will vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service through the vesting date. The RSUs will vest in full immediately prior to the consummation of a change in control of the Issuer. The RSUs will be settled in shares of the Issuer's common stock upon vesting.
SEC remarks
Exhibit 24 - Power of Attorney